October 30, 2018 admin

New Study Cites 82 Percent Mortality and 56 Percent Rehospitalization Reductions 30 Days After Therapy Guided by Daxor’s BVA-100 Blood Volume Analyzer in Acute Heart Failure Patients

Controlled Study of BVA-100 Published in The Journal of the American College of Cardiology – Heart Failure Showed 86 Percent Reduction in One-Year Mortality

NEW YORK – October 30, 2018 – Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces the publication of new data in the Journal of the American College of Cardiology – Heart Failure showing statistically significantly reduced 30-day readmission and 30-day and 1-year mortality rates in patients who received individualized treatment for acute heart failure guided by blood volume measurement with the BVA-100 blood volume analyzer, compared to propensity-matched controls.

“This is a landmark study for Daxor as it provides peer review validation in a leading cardiology journal of the value of our technology and its potential to improve heart failure outcomes.  Heart failure represents one of the largest areas of healthcare spending and one of the most significant treatment challenges for approximately 6 million US patients, which is expected to double as the population ages,” commented Michael Feldschuh, CEO of Daxor.  “The BVA-100 provides a simple, rapid, inexpensive, non-invasive, and most importantly, objective measurement of volume status and composition. This precision enables individualization of treatment and significantly better outcomes for patients.”

Treatment guided by the BVA-100 blood volume analyzer resulted in a statistically significant decrease in rehospitalization (12.2 percent vs. 27.7 percent, p<0.001), 30-day mortality (2.0 percent vs. 11.1 percent, p<0.001) and 365-day mortality (4.9 percent vs. 35.5. percent, p<0.001), compared to a propensity score control.  Further, an analysis of 30-day readmission by diagnosis showed fewer heart failure readmissions (6.1 percent vs. 20.2 percent, p<0.001) and fewer cardiac non-heart failure admissions (1.6 percent vs. 3.9 percent, p<0.001). 

“The results of this outcome study demonstrate without question that accurate blood volume measurement substantially improves the physician’s ability to prescribe decongestion therapy that will result in significantly better outcomes in acute heart failure, particularly with regard to rehospitalization and mortality,” said John E. Strobeck, M.D., Ph.D., Director, Heart-Lung Consultants, Inc., Hawthorne, NJ and lead author of the study. “These results clearly show that BVA measurement has a one-to-one relationship in achieving meaningful improvements in clinical and resource-use outcomes in patients hospitalized for acute heart failure.” 

Total blood volume, red blood cell volume and plasma volume were measured using Daxor’s BVA-100, an I-131 labeled albumin indicator dilution technique that is unique to the BVA-100.  Patients were assigned a decongestion and treatment strategy based on the BVA-100 measurement.  Propensity score control matching was derived from CMS data matching 10:1 for demographics, comorbidity and year of treatment.

About Daxor

Daxor Corporation is an innovative commercial-stage medical instrumentation and biotechnology company. The company manufactures the BVA-100 Blood Volume Analyzer, the only instrument cleared by the FDA to provide rapid direct measurement of a patient’s blood volume and optimal volume. Its mission is to help hospitals and physicians incorporate Daxor’s advanced technologies to significantly improve the quality of patient care. For more information please visit our website at https://daxor.com.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information:

Daxor Corporation

Soren Thompson 

Investor Relations



Investor Relations Contact:

Bret Shapiro

Sr. Managing Partner





Jules Abraham